Anthrax attacks

Dr. Steven Hatfill: Pandemic Report Single Point Failure II

Retrieved on: 
Thursday, May 27, 2021

OCALA, Fla., May 27, 2021 /PRNewswire/ -- Called to the White House in the early days of the pandemic as an outside advisor to the Executive Office of the President, DR. STEVEN HATFILL witnessed the destruction of the National Pandemic Plan.

Key Points: 
  • OCALA, Fla., May 27, 2021 /PRNewswire/ -- Called to the White House in the early days of the pandemic as an outside advisor to the Executive Office of the President, DR. STEVEN HATFILL witnessed the destruction of the National Pandemic Plan.
  • In the continuation of his article SINGLE POINT OF FAILURE (pub.
  • PCEN Media Inc. owns and operates MYTVTOGO consisting of over 100 broadcast networks viewed in 140+ countries.
  • For more information, please visit pcenmedia.com
    View original content to download multimedia: http://www.prnewswire.com/news-releases/dr-steven-hatfill-pandemic-repor...

Biopreparedness Expert Gustavo Palacios, PhD, to Join Mount Sinai, Strengthening Research Collaborations with Department of Defense

Retrieved on: 
Thursday, May 6, 2021

Public, private, government, and academic efforts are crucial to create a biopreparedness system for the country and the globe.

Key Points: 
  • Public, private, government, and academic efforts are crucial to create a biopreparedness system for the country and the globe.
  • We are excited to further strengthen our ties with government researchers and scientists who share a common goal of protecting public health."\nDr.
  • Palacios\'s transition to Icahn Mount Sinai is the first step to strengthen the relations and conduits between Mount Sinai and USAMRIID.
  • Research conducted at USAMRIID leads to medical solutionsvaccines, drugs, diagnostics, information, and training programsthat benefit both military personnel and civilians.

Dr. Steven Hatfill: Pandemic Report

Retrieved on: 
Thursday, April 29, 2021

b'OCALA, Fla., April 29, 2021 /PRNewswire/ -- Dr. Steven Hatfill, M.Med was called to the White House in the early days of the pandemic.

Key Points: 
  • b'OCALA, Fla., April 29, 2021 /PRNewswire/ -- Dr. Steven Hatfill, M.Med was called to the White House in the early days of the pandemic.
  • During his 13-month tenure in the West Wing as advisor to the Trump administration, Dr. Hatfill had a front row seat to the destruction of the National Pandemic Plan at the hands of career bureaucrats resulting in the deaths of countless Americans.\nThis week, Dr. Hatfill in conjunction with PCEN Media Inc , will release his latest article:\n"How a Single Point of Failure Destroyed the National Pandemic Plan"which exposes the petty political machinations of small minds and oversized egos.\nThe full article may be viewed and downloaded via the web: drstevenhatfill.com\nDr.
  • Steven Hatfill is a specialist physician and a virologist with a military background and separate master\'s degrees in microbial genetics, radiation biochemistry, and experimental pathology.\nPCEN Media Inc. owns and operates over 100 broadcast networks viewed in 140+ countries.\nPCEN Media Inc. is a subsidiary of PCEN Holdings Inc.The company owns and operates MYTVTOGO, an OTT platform with 70 networks (including the Planet Cannabis Entertainment Network), viewed in 60+ countries.Please visit https://pcenmedia.com/ for more information.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/dr-steven-hatfill-pandemic-repor...\n'

Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19

Retrieved on: 
Tuesday, April 28, 2020

USAMRIID will evaluate the constructs on characterized wild-type SARS-CoV-2 viruses for their potential to inhibit viral infection.

Key Points: 
  • USAMRIID will evaluate the constructs on characterized wild-type SARS-CoV-2 viruses for their potential to inhibit viral infection.
  • Based on the results, Sarepta and USAMRIID will consider collaborative funding proposals to advance the development of treatments for COVID-19.
  • Indeed, we have already built and manufactured therapeutic PPMO constructs and are providing them now to USAMRIID for testing and evaluation.
  • Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

2019 Half-year consolidated results: Deinove’s progress coming to fruition

Retrieved on: 
Thursday, September 26, 2019

Investigation centers have been selected and the enrolement of the first patient is expected in the coming weeks.

Key Points: 
  • Investigation centers have been selected and the enrolement of the first patient is expected in the coming weeks.
  • DNV3681 has demonstrated a higher in vitro efficacy than Ciprofloxacin, the reference product in the event of exposure to anthrax bacteria.
  • These data were presented at the American Society of Microbiology Congress, ASM Microbe 2019, by Major Steven Zumbrun, PhD in Microbiology at USAMRIID.
  • Dow has selected one of the extracts of interest from DEINOVE's bacterial collection based on promising in vitro results.

More Nerve Gas Attacks Likely, According to Journal of American Physicians and Surgeons

Retrieved on: 
Monday, March 25, 2019

TUCSON, Ariz., March 25, 2019 /PRNewswire/ --Recent nerve-gas attacks on civilians suggest the need for better preparedness, writes Steven Hatfill.

Key Points: 
  • TUCSON, Ariz., March 25, 2019 /PRNewswire/ --Recent nerve-gas attacks on civilians suggest the need for better preparedness, writes Steven Hatfill.
  • M.D., in the spring issue of in the Journal of American Physicians and Surgeons.
  • Russia is believed to have made significant advances in chemical warfare agents during the Cold War, despite the Chemical Weapons Convention.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

List Labs Announces New Anthrax Lethal Factor Detection Method

Retrieved on: 
Thursday, December 13, 2018

CAMPBELL, Calif., Dec. 13, 2018 /PRNewswire/ --Since the intentional release of anthrax spores leading to lethal inhalational anthrax in 2001, the need for rapid and sensitive detection of infection has been critical.

Key Points: 
  • CAMPBELL, Calif., Dec. 13, 2018 /PRNewswire/ --Since the intentional release of anthrax spores leading to lethal inhalational anthrax in 2001, the need for rapid and sensitive detection of infection has been critical.
  • This protein, anthrax lethal factor , is produced early in infection in a quantity sufficient for detection making it possible to rapidly determine that a patient is infected and to initiate therapy.
  • A reagent that specifically detects the presence of low amounts of lethal factor from anthrax infection is described.
  • This study sets a new standard for a sensitive, simple, and specific method to detect anthrax infection.